The Medical Advisor

Recently, celebrated cancer researcher Dr. Angus Dalgleish sang the praises of Ivermectin as a repurposed cancer drug that “ blocks more cancer pathways ” than he could fathom. He compared this with the established and accepted cancer treatment known as lenalidomide, sold under the trade name Revlimid, now a worldwide blockbuster first-line cancer treatment. Revlimid arose from the repurposing of thalidomide , a notorious drug that suppressed blood vessel growth in tumors. As a first-line cancer treatment for multiple myeloma, Revlimid retails for about $160,000 per year . Professor Dalgleish should know precisely how Ivermectin stacks up against this expensive Big Pharma drug as he co-authored much of the research on Revlimid. In the following interview (below), he explains the anti-cancer potential of Ivermectin, and why it may be superior to lenalidomide. “This is something I’m very familiar with as I did a lot of work with thalidomide at Celgene developing lenalidomide and pomali...